Aslan Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company, and Thermo Fisher Scientific, have entered a partnership to manufacture a high concentration formulation of eblasakimab for Phase 3 clinical trials. Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor that has the potential to deliver a differentiated efficacy and safety profile for the treatment of moderate-to-severe atopic dermatitis (AD). Aslan has developed a high ...